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 ABSTRACT 
Carbamazepine, an anti-epileptic pharmaceutical agent commonly found in 
wastewater, is highly recalcitrant to standard wastewater treatment practices. This 
study investigated the mixture toxicity of carbamazepine transformation products 
formed during ultraviolet (UV) photolysis using three standard ecotoxicity assays 
(representing bacteria, algae and crustaceans). UV-treatment of 6 mg L-1 
carbamazepine solution was carried out over a 120 min period and samples were 
removed periodically over the course of the experiment. Quantification results 
confirmed the degradation of carbamazepine throughout the treatment period, together 
with concurrent increases in acridine and acridone concentrations. Ecotoxicity was 
shown to increase in parallel with carbamazepine degradation indicating that the 
mixture of degradation products formed was more toxic than the parent compound, 
and all three ecotoxicity endpoints were still inhibited > 60 % relative to control 
populations upon dosing with 90+ min UV-treated carbamazepine solution. Single 
compound toxicity testing also confirmed the higher toxicity of measured degradation 
products relative to the parent compound. These results show that transformation 
products considerably more toxic than carbamazepine itself may be produced during 
UV-treatment of wastewater effluents and/or photo-induced degradation of 
carbamazepine in natural waters. This study highlights the need to consider mixture 
toxicity and the formation and persistence of toxicologically relevant transformation 
products when assessing the environmental risks posed by pharmaceutical compounds. 
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1. INTRODUCTION 
There are large knowledge gaps concerning the environmental fate and effects of most 
active pharmaceutical ingredients (APIs). For regulators, this translates to a high 
degree of uncertainty about the risks associated with pharmaceutically derived 
contaminants in the environment (Kümmerer, 2009a, 2009b). The quantities of APIs 
released to the environment may be relatively low in comparison with other types of 
pollutants such as pesticides and industrial pollutants, but there is a tendency for their 
environmental release to be continuous (via wastewater effluents) and the potential 
for environmental accumulation and/or chronic ecotoxicity has thus been noted (e.g. 
Besse and Garric, 2008; Fent et al., 2006; Ferrari et al., 2003; Hernando et al., 2006; 
Escher et al., 2011).  
 
Carbamazepine, an antiepileptic pharmaceutical compound and mood stabilising drug, 
has attracted particular attention in recent years due to its widespread detection in 
municipal wastewaters (e.g. Ternes, 1998; Ollers et al., 2001, Falås et al., 2012), 
surface waters (e.g. Ternes, 1998, Metcalfe et al., 2003; Andreozzi et al., 2003), and 
drinking waters (e.g. Heberer et al., 2004; Stackelberg et al., 2004, 2007; Togola and 
Budzinski, 2008;). It is also noted to be highly resistant to biodegradation and thus 
highly recalcitrant under standard biological wastewater treatment conditions (Clara 
et al., 2005; Kosjek et al., 2009, Falås et al., 2012). Under these circumstances, 
advanced oxidation processes (AOPs) may offer additional treatment value (von 
Gunten, 2003; Huber et al., 2005; Macova et al., 2010; Kosjek et al., 2011, Hey et al., 
2012; Keen et al., 2012), however complete oxidation and mineralisation is not 
always achievable and stable transformation products formed during AOPs may also 
pose environmental risks (Aguerra et al., 2005). The stability and ecotoxicity of 
transformation products formed during treatment and environmental transport are of 
major importance when assessing the suitability of water treatment options and in 
determining environmental risks associated with APIs in the environment.  
 
This paper presents the results of research investigating the ecotoxicity of 
carbamazepine and two of its UV transformation products (Kosjek, 2007), acridine 
and 9(10H)-acridone. Kosjek et al (2007) have also identified several other 
compounds which may form via UV photolysis of carbamazepine, however authentic 
standard compounds are not commercially available for these other degradation 
products. Thus, in addition to single compound testing of carbamazepine, acridine and 
acridone with three different standard test organisms (bacteria, algae, and crustacean), 
an experiment was also conducted to investigate the changes in ecotoxicity occurring 
during UV-treatment of water spiked with 6 mg L-1 carbamazepine. This experiment, 
conducted using a bench-top circulating flow UV-reactor system, was designed to 
compare the ecotoxicity of the initial carbamazepine-spiked solution with that of 
samples collected during the treatment process. These samples contained mixtures of 
carbamazepine and its UV-transformation products (including, but not limited to, 
acridine and acridone).  
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This study provides an example of the ‘effect-driven approach’ for determining the 
risks associated with pollutant transformation products. The ‘effect driven approach’, 
described by Escher and Fenner (2011) in their paper on advances in environmental 
risk assessment of transformation products, focuses on ecotoxicity testing of reaction 
mixtures in which a parent compound is undergoing degradation (e.g. during UV-
treatment). This approach facilitates prioritisation of APIs and their transformation 
products for risk assessment purposes without requiring the prior identification and 
quantification of individual transformation products and is thus ideal for situations 
such as this one in which standard compounds are not available for all relevant 
transformation products . In ‘effect driven’ assessments, compounds are prioritised for 
transformation product isolation, purification, and further study if the reaction mixture 
increases in toxicity in parallel with decreasing parent compound concentration. 
 
This investigation into the relative toxicity of carbamazepine and its 
phototransformation products is relevant to future discussions regarding the treatment, 
control and fate of carbamazepine and carbamazepine-derived contaminants in the 
environment. Knowledge about carbamazepine’s UV-induced degradation pathway is 
also of interest from the perspective of sunlight-induced photochemical oxidation, as 
this may be a significant process controlling the gradual ongoing breakdown of 
carbamazepine released to receiving waters and natural aquatic environments. Indeed, 
for non biodegradable, non-sorbing APIs such as carbamazepine, sun-induced 
photodegradation may be one of the most important long-term process affecting 
persistence and toxicity in the environment (Doll and Frimmel., 2003; Aguera et al., 
2005).  
 
2. METHODS 
2.1 Standards, Solvents, and Other Chemicals.  
Carbamazepine (99%, CAS 298-46-4) and N-Methyl-N- [tert-butyldimethyl-
silyl]trifluoroacetimide (MTBSTFA) were purchased from Acros Organics (New 
Jersey, USA). Acridine (97%, CAS 260-94-6) and 9(10H)-acridone (99%, CAS 578-
95-0) were obtained from Sigma-Aldrich (St. Louis, USA). Stock solutions were 
freshly made prior to use and the volumetric flasks were covered in aluminium foil to 
prevent photodegradation. 
 
2.2 Chemical analyses 
Solid phase extraction (SPE) was used for sample preparation for all chemical 
analyses. Concentrated solutions (i.e. stock solutions and selected concentration check 
samples from the acute toxicity test dilution series) were initially diluted as 
appropriate (dilution factors ranged from 17 to 600) before loading at neutral pH onto 
Oasis® HLB reversed-phase sorbent SPE cartridges (Waters, Corp., Milford, MA, 
USA). These cartridges were also used for preconcentration of the 150 mL 
subsamples taken throughout the carbamazepine UV-treatment experiment. SPE 
cartridges were conditioned with 3 mL of ethyl acetate, 3 mL methanol, and 3 mL of 
tap water. Sample aliquots were loaded on the SPE columns at a flow-rate of 4–5 mL 
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min−1. Each cartridge was then washed with water (3 mL), dried for 30 min under 
vacuum and eluted with 1 mL acetone, 1 mL of 7/3 ethyl acetate / acetone mixture 
and 1 mL of ethyl acetate. The combined eluant was evaporated to dryness under a 
gentle nitrogen stream and reconstituted with 0.5 mL ethyl acetate.  
 
Acridone and carbamazepine were transformed into the tert-butyldimethyl-silyl ether 
derivatives by adding 30 μL MTBSTFA and maintaining the samples at 60°C for 12 
hours. A Varian 3800 gas chromatograph (GC) interfaced with an ion trap Saturn 
2000 mass spectrometer (MS) was used for analysis. 10 μL samples were injected 
(split-splitless) using a PTV injector at 80 °C for 0.30 min before being increased by 
200°C/min to 300°C and held for 5 min. A Zebron ZB-5 HT INFERNO 30 m × 0.25 
mm × 0.25 μm (Phenomenex) column was used for separation. The GC oven 
temperature programme was originally held at 80°C for 1 min, then increased by 
25°C/min to 225°C and held for 1 min; increased by 1°C/min to 231°C; increased by 
10°C/min to 280°C; increased by 45°C/min to 320°C and held at 320°C for a further 3 
min. The total runtime was 22.59 min. The mass analyser was operated in electron 
ionisation (EI) mode, and the following fragment ions were monitored for 
quantitation: m/z 179 for acridine, and m/z 252 and m/z 193 for the acridone-MTBS 
and carbamazepine-MTBS derivatives respectively.  
 
For each sample, two parallel subsamples were extracted, derivatised and analysed 
according to the above protocol. Furthermore, each of these subsamples was injected 
and analysed twice, with the mean value taken as the relevant concentration. Method 
performance analyses showed satisfactory linearity (r2 > 0.98) and good repeatability 
for all three analytes. Blank control samples were also prepared and analysed. The 
limits of detection (LOD) were 2.3 μg L-1 for acridine, 14 ng L-1 for acridone and 11 
ng L-1 for carbamazepine 
 
2.3 Ecotoxicity testing 
Three internationally standardised aquatic ecotoxicity tests (Table 1) were used to 
investigate the ecotoxicity of carbamazepine, acridine, and acridone. The same three 
assays were also used to monitor changes in ecotoxicity during UV-treatment of the 6 
mg L-1 carbamazepine solution. All measurements were conducted in triplicate. The 
selected ecotoxicity tests used organisms from different trophic levels and included 
the following short-term toxicity tests: 
 inhibition of bioluminescence in the marine bacterium Vibrio fischeri (Biotox 
testing kit; ISO 11348-3, 1998);  
 growth inhibition of the green algae Pseudokirchneriella subcapitata (ISO 8692, 
2004);  
 immobilisation of the crustacean Daphnia magna Straus (Cladocera, Crustacea) 
(ISO 6341, 1996).  
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Table 1: Summary of experimental conditions for bacteria, algae, and daphnia ecotoxicity assays  
 Bacteria Algae Cladoceran 
Test species 
Vibrio fischeri 
(Photobacterium 
phosphoreum) 
Pseudokirchneriella 
subcapitata 
(Selenastrum 
capricornatum) 
Daphnia magna 
Temperature (°C) 15 20 20 
Optimal pH 7.0 ± 0.2 7.8 ± 0.2 8 ± 0.3 
Light source - 
Light intensity of 
10,000 lux supplied by 
cool white fluorescent 
tubes 
Darkness 
Media volume 200 µl/ vial 4 ml/ vial 50 ml/ vial 
Number of  
organisms 
exposed 
Variable 5-10·103 cells/ml 5 juvenile Daphnia per beaker 
Aeration 
Test vial is left 
uncovered during the 
test 
Constant air exchange 
through a hole in the lid 
of each growth vial 
Limited aeration 
(beakers are covered by 
a watch glass during the 
test) 
Test duration 30 min 48h 48h 
Replicates 3 - 6 3 - 6 2 - 3 
Assessment 
endpoint 
Inhibition of 
bioluminescence  Biomass growth Daphnia immobilisation 
Measurement 
endpoint Luminescence 
Chlorophyll 
fluorescence 
Number of immobilised 
daphnia 
International 
Standard 
Organisation 
(ISO) Reference 
ISO 11348-3, 1998  ISO 8692, 2004  ISO 6341, 1996  
 
For the Biotox test, 950 µL of sample solution and 50 µL of V. fischeri culture were 
mixed and bioluminescence was measured after 5, 15 and 30 min exposure to the test 
solution. Algal biomasses were determined using acetone pigment extractions as 
described by Mayer et al., (1997). For all three ecotoxicity tests, range finding tests 
were initially conducted for each compound and test species, prior to definitive tests 
combining ecotoxicity testing and test compound quantification. The aim was to 
obtain Effective Concentration values (i.e. EC10 and EC50) for each individual 
compound. In cases where complete inhibition/immobilisation of the test 
organism/endpoint did not occur within the solubility limits of the test compound, the 
assay was re-run with six replicates and LOEC/NOEC values were determined. All 
bioassays were conducted under static conditions with no renewal of the test solution. 
Dissolved oxygen and pH were measured at the beginning and end of each testing 
period to check compliance with standard test conditions. Quality control tests with 
potassium dichromate were also performed (K2Cr2O7 EC50 0.8 – 1.4 mg L-1). All 
ecotoxicity results are reported in terms of the toxic response relative to a measured 
control population. To be considered as valid results, population growth of algae 
control treatments must be exponential and immobilisation of Daphnia control 
populations must be < 10 %. In addition to standard control samples, 
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DMSO/methanol solvent controls were also included. The test results for solvent 
controls did not differ significantly from ordinary controls and were used to represent 
the control population for statistical analyses).  
 
2.4 Preparation of solutions for ecotoxicity testing 
Stock solutions for ecotoxicity testing of individual compounds were prepared in 
dimethylsulphoxide (DMSO). An aliquot of each stock solution was then diluted in 
ultra-pure water (MilliQ) to prepare the top concentration for ecotoxicity testing and 
further diluted using the appropriate growth medium to prepare the full concentration 
series for each test. The highest concentrations of solvent in the test solutions were 
always < 0.1 % of the total volume of test solution. The stock solution for the 6 mg L-
1 carbamazepine UV-treatment test was prepared in methanol. The concentration of 
methanol in the starting solution was 0.1 %. 
 
2.5 UV-treatment of carbamazepine and related ecotoxicity assessments 
UV-treatment of a 6 mg L-1 carbamazepine solution (prepared with MilliQ water) was 
conducted using a bench scale UV photoreactor with a circulating flow system. This 
experiment was carried out in triplicate. The apparatus consisted of a steel container 
(8 L), a waterpump (85 L h-1), and a medium pressure metal-halogen UV lamp (690 
W). The UV lamp (Bau 42, Scan Research A/S, Denmark) emitted a polychromatic 
light (λ = 185-400 nm) with enhanced emission in the relevant range for 
photochemical treatment (i.e. 190-250 nm). The emission spectrum for this lamp has 
been previously reported (Kosjek et al., 2009).  
 
The fate and behaviour of carbamazepine and its transformation products were 
studied over a 120 min irradiation period. A stock solution of 60 mg carbamazepine in 
10 mL of methanol was prepared and gradually added to 10 L of MilliQ water to give 
a 6 mg L-1 carbamazepine solution. This was allowed to circulate through the flow 
system for 10 min prior to the beginning of the test in order to allow for thorough 
mixing of the test solution. The first 150 mL sample (Time 0) was then taken. 
Subsequent samples were removed after 2, 5, 10, 15, 20, 25, 30, 45, 60, 90, and 120 
min of UV exposure. For each sampling event the lamp was switched off following 
the predetermined exposure period and the system left to circulate for a further 5 min 
before sampling. The temperature of the test solution increased during treatment, 
however ice was used to blanket the UV-treatment system to maintain the temperature 
below 50 °C at all times in order to limit thermal degradation. Carbamazepine, 
acridine and acridone concentrations were quantified throughout the UV-treatment 
process using the SPE and GC-MS method described above. All samples were stored 
at 4 ºC prior to chemical and ecotoxicological analyses. 
 
2.6 Dose-response calculations and other statistical analyses 
Dose-response data for the V. fischeri bioassays were fitted using a log–logistic 
distribution, and EC10, EC50 values and their 95 % confidence intervals were 
calculated as in Broos et al. (2007). For the P. subcapitata bioassays, algal growth 
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rate was calculated from the logarithmic increase in cell density in each individual 
algae culture, assuming exponential growth during the 48-h duration of the assay. 
Algal data analysis, including calculation of probit and Weibull dose–response 
models,  EC50 and EC10 values and their 95 % confidence intervals was carried out 
using a Windows-based dose–response regression tool programmed by K.O.Kusk 
which functions according to the method described in Christensen et al., (2009). D. 
magna bioassay results were analysed using the Toxicity Data Analysis and Database 
Software (ToxcalcTM v5.031), which generates median effective concentrations and 
their 95% confidence intervals and probit values. All other statistics presented in this 
paper were calculated using Microsoft Office Excel. 
 
3. RESULTS 
3.1 Ecotoxicity of carbamazepine, acridine and acridone 
Acute toxicity data for the individual compounds, expressed either as median 
effective concentrations (EC10/EC50) or NOECs and LOECs are presented in Table 2. 
The results of all three acute toxicity assays showed the parent compound, 
carbamazepine, to be significantly less toxic than either acridine or acridone. 
Furthermore, of the two transformation products tested, acridone was consistently less 
toxic than acridine across all three assays. Table 3 presents a comprehensive list of 
published aquatic ecotoxicity test results for these three compounds. These values 
clearly support the results presented above, strongly suggesting that UV photolysis of 
carbamazepine can produce degradation products of greater toxicity that the parent 
compound  itself. 
 
Table 2: Ecotoxicity testing results for carbamazepine, acridine and acridone (all values in mg L‐1). Results are 
based on measured solution concentrations. For tests where full response curves were obtained n = 39. For 
tests where full response curves could not be obtained additional NOEC/LOEC tests were run. NOEC/LOEC tests 
comprised 6 replicates for each concentration tested).  
Ecotoxicity Assay Carbamazepine Acridine Acridone 
Bacteria, Vibrio fischeri  
(5, 15, 30 min); inhibition 
of bioluminescence 
NOEC = 5.59 
LOEC = 8.16 
EC10 = 0.78 – 0.98 
EC50 = 5.34 - 6.90 
NOEC = 0.99 - 2.10 
LOEC = 1.44 - 3.07 
Algae, Pseudokirchneriella 
subcapitata (48 h); 
inhibition of growth 
 NOEC = 
27.4LOEC = 40 
 
EC10 = 0.11 
EC50 = 0.61  
NOEC = 0.69 
LOEC = 1.09 
Cladoceran, Daphnia 
magna (48 h); 
immobilisation 
NOEC = 30  
 
EC10 = 0.39 
EC50 = 0.71 
EC10 = 0.82 
EC50 = 1.49 
 
 
3.2 Carbamazepine UV-treatment experiment 
Experiments to investigate the effects of UV-treatment of 6 mg L-1 carbamazepine 
solution were carried out over a 120 min period and samples were removed 
periodically over the course of these experiments for chemical analysis and 
ecotoxicity testing. Chemical quantification analyses were performed on duplicate 
samples taken during one of the 6 mg L-1 carbamazepine UV-treatment tests, whilst 
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ecotoxicity endpoints were measured on samples from three replicate UV-treatment 
experiments (n = 9). The starting concentration of 6 mg L-1 carbamazepine is higher 
than measured environmental concentrations (Lacey et al., 2012), but facilitated the 
collection of measureable toxicity data from beginning to end of the UV-treatment 
experiments.  
 
Table 3: Comprehensive listing of all published aquatic organism acute (short‐term) toxicity data for 
carbamazepine, acridine, and acridone. EC50/LC50 values relate either to solution concentrations or porewater 
concentrations as relevant to the particular test. All values are given in mg L‐1. 
Organism, test duration, and 
ecotoxicological endpoint 
Carbamazepine 
EC50/LC50  
Acridine  
EC50/LC50 
Acridone 
EC50/LC50 
Bacteria (Vibrio fischeri); 5/15/30 min; 
bioluminescence (aKim et al., 2007; 
bFerrari et al., 2003; cJos et al., 2003) 
52.2a  
> 81b  
64 -  79c  
  
Algae (Chlorella vulgaris); 48 h; growth 
inhibition (Jos et al., 2003) 
37  
 
  
Cladoceran (Daphnia magna); 48 h; 
immobilisation (aKim et al., 2007; 
bFerrari et al., 2003; cJos et al., 2003; 
dCleuvers, 2002); (Ceriodaphnia dubia); 
48 h; immobilisation  
(e Ferrari et al., 2003) 
>100a  
> 13.8b 
98c 
> 100d 
77.7e 
 
  
Cnidarian (Hydra attenuata); 96 h; tulip 
phase morphology; (Quinn et al., 2008) 
29.4  
 
  
Bivalve, Zebra mussel (Dreissena 
polymorpha); 96 h; cell cytoxicity; 
haemocytes, gill and digestive gland 
cells; (Parolini et al., 2011) 
5.1 – 6.8   
Algae spp. (multiple species tested); 96 h 
growth inhibition (aDijkman et al., 1997); 
24 h growth inhibition bEisentraeger et 
al., 2008) 
 0.08 – 0.79a 
2.1b  
 
 
Cladoceran (Daphnia spp.); 24/48 h; 
immobilisation (aSouthworth et al., 1978; 
bEisentraeger et al., 2008; cParkhurst et 
al., 1981) 
 1.71a 
4.6b  
2.3c 
 
 
Benthic invertebrate, midge (Chironomus 
riparius); 96 h; survival (first instar 
larvae) (Bleeker et al., 1998) 
 0.07  
 
 
Bivalve, Zebra mussel (Dreissena 
polymorpha); 48 h; filtration rate (Kraak 
et al., 1997) 
 0.96  
 
 
Calonoid copepod (Diaptomus clavipes); 
14 h; mortality (first naupliar) (Cooney 
and Gehrs, 1984) 
 1.55  
 
 
Benthic invertebrate, midge (Chironomus 
riparius); 96 h (Bleeker et al., 1999) 
 0.40 
 
> 4.8 
 
 
 
Quantification results confirmed the ongoing degradation of carbamazepine 
throughout the 120 min treatment period, together with concurrent increases in 
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acridine and acridone throughout the first 20 min of treatment (Figure 1). These 
compounds, which were not present at Time 0, were quantifiable in solutions sampled 
from 2 - 90 min after the onset of UV-treatment, confirming the formation of these 
compounds as a function of the UV-photolysis of carbamazepine (see Kosjek et al., 
2009). However, from 25 min onwards the measured concentrations of both acridine 
and acridone consistently decreased, indicating that the transformation rates of these 
compounds were greater than their production rates for the remainder of the 
experimental period. Both compounds were below detection limits after 120 min of 
UV-treatment. The degradation of these compounds during the treatment period 
indicates that additional photolysis products were likely to have been produced during 
the remaining treatment period (see discussion below).  
 
Figure 1. Measured concentrations of carbamazepine, acridine, and acridone in samples removed periodically 
from a 6 mg  L‐1 carbamazepine UV‐treatment experiment. Measurements were  carried out  in duplicate and 
both results are plotted. 
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Although methanol, a potential radical scavenger, was used as the solvent for the 
carbamazepine stock solution, Kosjek et al. (2009) showed that the concentration of 
methanol used in this experiment should not have inhibited the decay of 
carbamazepine or the identified transformation products during treatment. Their 
investigation using the same benchtop UV-treatment system as the current experiment 
showed no significant difference in carbamazepine decay in the presence of 1.2, 2.5 
and 6.2 % methanol. As the experimental design for the study reported in this paper 
included only 0.1 % methanol by volume, the presence of methanol is not believed to 
have affected the chemical analysis results obtained.  
 
The pH of the carbamazepine UV-treatment test solution decreased during treatment 
from ~ pH 5.8 to pH 3.6. This decrease in pH is unlikely to have caused significant 
degradation of carbamazepine as the recovery of carbamazepine from a 1.5 M HCl 
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solution after 48 h has been reported to be 97.3% (Rao and Belorkar, 2010). However, 
it was necessary to amend all samples to a standardised pH prior to ecotoxicity testing 
in order to prevent pH-induced toxic responses (i.e. hydrogen ion toxicity) from 
confounding the results. Samples were therefore amended with 0.1 M NaOH to obtain 
the appropriate pH range for each test organism (i.e. ~ pH 7 for V. fischeri; pH 7.8 for 
D. magna; pH 8 for P. subcapitata). Figure 2 summarises the results from the three 
ecotoxicity bioassays. The toxic response for all endpoints increased over time during 
the UV-treatment experiments in parallel with the formation of carbamazepine 
degradation products. These results indicate that the mixture of transformation 
products formed (including those which could not be quantified due to the lack of 
available standard compounds) was more toxic than the parent compound by itself.  
 
Figure 2. Measured toxic response of Vibrio fischeri (inhibition in bioluminescence, 15 min), 
Pseudokirchneriella subcapitata (growth inhibition, 24 h), and Daphnia magna (immobilisation, 48 h) exposed 
to solutions sampled from triplicate runs of the 6 mg L‐1 carbamazepine UV‐treatment experiment. Error bars 
represent the standard error of the mean (n=9). 
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Peak toxicity to V. fischeri occurred around 30 min after the onset of UV-treatment 
when concentrations of acridine and acridone were also near their highest (0.12 and 
0.0007 mg L-1 respectively). The inhibition of V. fischeri bioluminescence remained 
around 70 % from 25 min to 120 min UV-treatment. As the acridine and acridone 
concentrations were below their respective detection limits by 120 min (Figure 2) and 
concentrations of all individual compounds quantified were well below their EC50 
values (Table 2), it appears that other transformation products (discussed below) must 
also have contributed to the ongoing toxic response evident in Figure 2. This is also 
supported by the results of the P. subcapitata bioassay. In this case, growth inhibition 
reached 100 % within 20 min of the onset of UV-treatment and stayed at 100 % in all 
subsequent samples (i.e. up to 120 min UV-treatment). D. magna was less sensitive to 
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the mixture toxicity of the UV-treated carbamazepine solution and only demonstrated 
a measurable toxic effect (i.e. Daphnia immobilisation) after 45 min of UV-treatment. 
However, in keeping with the other bioassays, the effect was still evident at the end of 
the experiment, indicating that toxic transformation products still remained in the 
solution at the end of the treatment period. 
 
For clarity of presentation only the 15 min V. fischeri, 24 h P. subcapitata, and 48 h D. 
magna test results are shown in Figure 2. However, it should be noted that the 
response data for the 5, 15, and 30 minute V. fischeri exposure measurements were all 
very similar, both in terms of the overall response pattern and the measured inhibition 
values. The D. magna 24 h and 48 h measurements also compared favourably in terms 
of the pattern of response, and indicated a stronger toxic response after a longer 
exposure period (i.e. 48 h) as would typically be expected. Similarly, the 48 h P. 
subcapitata results showed greater growth inhibition in the 2, 5 and 10 min UV-
treatments than was observed for the 24 h P. subcapitata measurement. The rest of the 
samples (20 – 120 min UV-treatment) showed 100 % growth inhibition for both 24 h 
and 48 h measurements. The most interesting difference observed in the P. 
subcapitata tests was the apparent toxicity (~ 54 % growth inhibition) in the 48 h 
exposure test of the Time 0 samples (data not shown). This response indicates that 
some photodegradation may have occurred in the Time 0 sample throughout the algae 
test itself. The growth lamp used for the algae tests (Philips TL-D 30W/33-640) 
mainly emits light in the visible region (> 400 nm) but also has a narrow emission 
peak at 365 nm. The V. fisheri test is much shorter (30 min) than the P. subcapitata 
test and does not involve significant illumination, whilst the D. magna test is carried 
out in the dark. Thus it is certainly plausible that the effects of in-test 
photodegradation would only be seen in the P. subcapitata results. 
 
4. DISCUSSION 
The presented results clearly indicate that the photodegradation products, acridine and 
acridone, are considerably more toxic than the parent compound carbamazepine 
across multiple trophic levels. Although the sensitivities of the different test 
organisms differed, all species showed greater toxicity of the tested photodegradation 
products compared with the parent compound carbamazepine and this result was 
further reflected in the increasing toxicity of the carbamazepine spiked water 
throughout the UV-treatment experiment. This is the first time that these compounds 
have been tested simultaneously under the same experimental conditions and using 
the same suite of assays, however we note that the results compared favourably with 
other published acute toxicity data for these compounds (Table 3).  
 
Recent efforts to quantify concentrations of carbamazepine in surface waters suggest 
that current environmental levels are well below the concentrations likely to cause 
acute toxicity to aquatic organisms. For instance, Lacey et al., (2012) referenced ten 
different studies measuring carbamazepine concentrations in wastewater influents and 
effluents across Europe and the USA, and reported a maximum effluent concentration 
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across those studies of 6.5 µg L-1. This is three orders of magnitude smaller than the 
lowest carbamazepine effect concentration measured in this experiment (V. fischeri, 
LOEC 8.16 mg L-1). However, studies which have investigated chronic/sublethal 
impacts of pharmaceutical compounds, including carbamazepine, have typically 
observed physiological effects at much lower contaminant concentrations than the 
measured threshold concentrations for acute toxicity. For example, Lurling et al., 
(2006) conducted chronic ecotoxicity tests using Daphnia pulex and observed 
significantly reduced rates of population growth at carbamazepine concentrations of 
200 µg L-1 due to retardation of juvenile somatic growth and subsequent delays in 
maturation and time to first reproduction. Similarly, Ferrari et al., (2003) reported 
carbamazepine NOEC and LOEC values of 25 µg L-1 and 100 µg L-1 respectively for 
a chronic 7-day test using reproduction of Ceriodaphnia dubia as the endpoint. These 
studies show that chronic carbamazepine exposure effects may occur at 
concentrations at least 3 orders of magnitude lower than the EC50 typically reported 
for acute Daphnia assays (e.g. this paper; Cleuvers, 2002; Jos et al., 2003; Kim et al., 
2007), and indicate that, based on estimates of ‘predicted no effect concentrations’ 
and ‘predicted environmental concentrations’ (Ferrari et al., 2003), carbamazepine 
poses a potential risk to aquatic environments. Given the current findings regarding 
the comparative ecotoxicities of carbamazepine and its UV-degradation products, this 
risk could be greater than was previously supposed. 
 
As stated previously, carbamazepine is continually released to the environment at low 
concentrations due to its ubiquitous presence in wastewater effluents. It is assumed 
that the removal of carbamazepine from surface waters will occur largely via the 
photodegradation pathway as sorption of carbamazepine is very limited (Ternes et al., 
2002; Scheytt et al., 2005; Clara et al., 2004) and it is resistant to biodegradation 
(Clara et al., 2004; Kosjek et al., 2009). Hence, the formation of stable 
photodegradation products is not only relevant to wastewater treatment processes, 
where UV-treatment may be implemented to assist with microbial disinfection (e.g. 
inactivation of Cryptosporidium); it is also relevant to the breakdown of 
carbamazepine in natural river environments. With this in mind it is important to note 
the recalcitrance of the degradation products formed during this experiment. Even 
though progressive mineralisation could not be monitored by means of Total Organic 
Carbon analysis due to the presence of methanol in the spiking solution, the persistent 
toxicity at the end of the UV-treatment experiment provides evidence that complete 
mineralisation did not occur. Previous research (Kosjek et al., 2009) has shown that at 
least six photochemical derivatives are likely to form during the UV degradation of 
carbamazepine. Acridine and acridone were positively confirmed by these researchers 
as carbamazepine UV photolysis degradation products through the use of 
commercially available authentic compound standards and multiple analytical 
techniques, whilst hydroxy-(9H,10H)-acridine-9-carbaldehyde, acridone-N-
carbaldehyde, and 1-(2-benzaldehyde)-(1H,3H)-quinazoline-2,4-dione were 
tentatively identified using gas chromotogaphy hyphenated with an ion trap mass 
spectrometer (GC-IT). It should also be noted that Li et al., (2011) reported that 
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oxycarbazepine, a keto analogue of carbamazepine which is increasingly used as a 
substitute, also degrades to form essentially the same suite of UV degradation 
products as carbamazepine. These authors also reported a toxic response in D. magna 
upon exposure to UV-treated oxycarbazepine solutions. By contrast, Rizzo et al., 
(2009) observed decreasing toxicity when 5 mg/L carbamazepine solution was treated 
by TiO2 photocatalysis, but it should be noted that the degradation pathway under that 
treatment regime (see Calza et al., 2012) would be different to the uncatalysed 
photolysis pathway relevant in this experiment.  
 
The UV dose applied in the current experiment is higher than that typically used for 
UV disinfection of water. A typical disinfection dose is equivalent to the UV dose 
delivered in less than 1 min in the current experimental setup. Hence, even though 
some degradation products may begin to form during UV disinfection (note that toxic 
effects were observed in samples taken only 2 min after the onset of UV-treatment) 
UV-disinfection doses are unlikely to significantly degrade carbamazepine. By 
contrast, if UV were to be purposely used as an end of pipe of treatment to photolyse 
chemicals the UV dose would be much higher, although not necessarily high enough 
to remove all toxic degradation products within a feasible timeframe. The feasibility 
of applying the UV lamp used in this study for degradation of both carbamazepine 
and other pharmaceuticals and estrogenic chemicals has been evaluated in previous 
studies (Hansen et al., 2007; Hansen and Andersen, 2012). Recalculating the doses 
from that study to the current laboratory setup indicates that 90 % removal of steroid 
estrogens would be equivalent to 2-5 min treatment (Hansen and Andersen, 2012), 
whereas some pharmaceuticals would require the equivalent of 20-40 min UV-
treatment to be degraded by 90 % (Hansen et al., 2007).  
 
In this study, mixture toxicity was still high (> 60 % toxic response relative to control 
populations for all endpoints) at the end of the UV-treatment experiment (Figure 2), 
even though the carbamazepine concentration had decreased to ~ 1 % of the starting 
concentration and acridine and acridone concentrations had declined to < 10 % of 
their peak concentrations. These results highlight the need to further consider the 
identity, stability, and environmental relevance of recalcitrant carbamazepine 
degradation products. Researchers have already noted that other pharmaceuticals, 
such as prednisone (DellaGreca et al., 2003) and diclofenac (Schulze et al., 2010), 
may also form transformation products more toxic than the parent compound. Failing 
to account for toxicologically relevant transformation products can easily lead to 
substances being incorrectly identified as posing negligible environmental risks, when 
in fact they are significant. However, systematic ecotoxicity testing of treatment 
transformation products is complicated by the complexity of the relevant degradation 
pathways and the large numbers of intermediate compounds of varying stability 
which can be formed (e.g. Agüera et al., 2005; Kosjek et al., 2009; Calza et al., 2012; 
Li et al., 2012). Moreover, degradation pathways may differ depending on the 
particular wastewater treatment regime or natural degradation pathway in question 
(e.g. activated sludge treatment or advanced oxidation vs. sunlight induced 
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photodegradation). It is unrealistic to expect that all relevant compounds can be tested 
using conventional toxicity testing of individual compounds at multiple trophic levels, 
especially as the majority of these substances may not be commercially available. 
Identification, synthesis and isolation of such compounds is extremely time 
consuming, making experiments such as this, where mixture toxicity of the 
degradation products together as a whole is assessed, particularly useful for 
identifying cases where degradation pathway toxicity may be an issue. Further 
information on effect-driven approaches for assessing the toxicological relevance of 
transformation products can be found in Escher and Fenner’s critical review (2011). 
 
5. CONCLUSION  
The results of this study indicate that degradation products considerably more toxic 
than carbamazepine itself may be produced as a result of UV-treatment of wastewater 
effluents and/or photo-induced degradation of carbamazepine in natural waters. These 
findings are clearly relevant to ongoing debates regarding the potential environmental 
effects of pharmaceutically-derived compounds in the environment, highlighting the 
need to consider mixture toxicity and the formation and persistence of toxicologically 
relevant degradation products when assessing environmental risk.  
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